Insulet Corp. Stock
Price
Target price
€126.85
€126.85
0.590%
0.75
0.590%
€306.79
19.06.26 / Tradegate
WKN: A0MQX8 / Symbol: PODD / Name: Insulet / Stock / Healthcare Equipment & Supplies / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Insulet Corp. Stock
Insulet Corp. gained 0.590% compared to yesterday.
The stock is one of the favorites of our community with 58 Buy predictions and 1 Sell predictions.
With a target price of 306 € there is potential for a 141.23% increase which would mean more than doubling the current price of 126.85 € for Insulet Corp..
So far the community has only identified positive things for Insulet Corp. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Insulet Corp. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
S********** s********
?
G***** c******* t* c**********
Cons
?
M***** P*******
?
B****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Insulet Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Insulet Corp. | 0.590% | -2.008% | -4.767% | -51.193% | -48.055% | -51.249% | -46.364% |
| Haemonetics Corp. | 0.770% | -5.147% | 33.264% | - | -5.839% | - | - |
| Bio-Rad Labs Inc. A | 0.080% | -2.057% | 2.314% | 23.307% | -3.994% | -28.065% | -53.283% |
| CONMED Corp. | 0.000% | -5.369% | -9.615% | -37.611% | -19.429% | -77.073% | -75.690% |
Comments
Insulet (PODD) had its "buy" rating reaffirmed by Benchmark Co..
Show more
Ratings data for PODD provided by MarketBeat
Insulet (PODD) had its "outperform" rating reaffirmed by Royal Bank Of Canada. They now have a $280.00 price target on the stock.
Show more
Ratings data for PODD provided by MarketBeat
Insulet (PODD) had its "buy" rating reaffirmed by The Goldman Sachs Group, Inc..
Show more
Ratings data for PODD provided by MarketBeat
News
Is Insulet (PODD) the Future of Diabetes Management?
Explore the exciting world of Insulet (NASDAQ: PODD) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market
